Executive Summary
MBPharmaco Consulting provides strategic clinical pharmacology and model-informed drug development (MIDD) expertise to pharmaceutical and biotechnology companies across early and late-stage development.
With four decades of industry experience, we support translational decision-making through integrated PK/PD, biomarker, exposure–response, and simulation-based approaches to optimise candidate selection, dose strategy, and clinical development planning.
Our expertise spans oncology, biologics, immunology, and complex translational pharmacology, supported by high-quality regulatory documentation and submission-ready clinical pharmacology deliverables.
Our mission is to accelerate development decisions and support the timely delivery of innovative medicines to patients.
Read MoreAccelerate your drug development by leveraging QCP principles and Model-informed drug development (MIDD). Our experienced team offers strategic guidance on clinical strategy and the design, execution, analysis, and reporting of clinical pharmacology studies.
Read More
Achieve better decision-making, minimise risk and reduce development costs with our MIDD services. We leverage quantitative clinical pharmacology to optimise drug development strategies and support regulatory submissions.
Read More
MBPharmaco Consulting offers expert clinical pharmacology regulatory writing assistance for NDA/BLA regulatory submissions (2.7.1 & 2.7.2) on a global scale. Our team collaborates closely with clinical pharmacology teams, ensuring the timely delivery of high-quality documents.
Read More
Don’t hesitate to ask us questions! Fill in the form below and we will respond you shortly! We value any feedback!